Gosse Bote Bruinsma
Vorstandsvorsitzender bei FAAH Pharma, Inc.
Profil
Gosse Bote Bruinsma currently works at FAAH Pharma, Inc., as Chief Executive Officer and viDA Therapeutics, Inc., as Director.
Dr. Bruinsma also formerly worked at Axonyx, Inc., as President, Chief Executive Officer & Director in 2006, IDEA AG, as Chief Executive Officer & Member-Management Board from 2012 to 2014, Vivendy Therapeutics Ltd., as Chief Executive Officer from 2009 to 2013, Curidium Medica Ltd., as Executive Chairman from 2007 to 2009, Forest Laboratories, Inc., as Medical Director, GT Biopharma, Inc., as Director, ClinTrials Research, Inc., as Medical Director, VP-Medical & Regulatory Affairs, Agendia NV, as Director, Zambon Company SpA, as Medical Director-European Division, Opsona Therapeutics Ltd., as Non-Executive Director, Janssen Vaccines & Prevention BV, as Vice President-Development, and Chrysalis, as General Manager & Vice President-Development.
Dr. Bruinsma received his undergraduate degree from McGill University and doctorate degree from the University of Leiden.
Aktive Positionen von Gosse Bote Bruinsma
| Unternehmen | Position | Beginn |
|---|---|---|
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Vorstandsvorsitzender | - |
viDA Therapeutics, Inc.
 viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Gosse Bote Bruinsma
| Unternehmen | Position | Ende |
|---|---|---|
Vivendy Therapeutics Ltd.
 Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Direktor/Vorstandsmitglied | 10.03.2014 |
Curidium Medica Ltd.
 Curidium Medica Ltd. Pharmaceuticals: MajorHealth Technology Curidium Medica Ltd. engaged in the development targeted medicines and companion diagnostics used in the medical sector. The company was founded on July 25, 2003 and was headquartered in Wetherby, the United Kingdom. | Vorsitzender | 08.01.2009 |
Axonyx, Inc.
 Axonyx, Inc. Pharmaceuticals: MajorHealth Technology Axonyx, Inc. is an biopharmaceutical company, which manufactures medical products and technologies to treat Alzheimer's disease and other Central Nervous System disorders. It is located in New York, NY. | Vorstandsvorsitzender | 06.10.2006 |
Janssen Vaccines & Prevention BV
 Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Corporate Officer/Principal | - |
ClinTrials Research, Inc.
 ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Gosse Bote Bruinsma
| McGill University | Undergraduate Degree |
| University of Leiden | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GT BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
ClinTrials Research, Inc.
ClinTrials Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million. | Commercial Services |
Axonyx, Inc.
Axonyx, Inc. Pharmaceuticals: MajorHealth Technology Axonyx, Inc. is an biopharmaceutical company, which manufactures medical products and technologies to treat Alzheimer's disease and other Central Nervous System disorders. It is located in New York, NY. | Health Technology |
Curidium Medica Ltd.
Curidium Medica Ltd. Pharmaceuticals: MajorHealth Technology Curidium Medica Ltd. engaged in the development targeted medicines and companion diagnostics used in the medical sector. The company was founded on July 25, 2003 and was headquartered in Wetherby, the United Kingdom. | Health Technology |
IDEA AG
 IDEA AG Pharmaceuticals: MajorHealth Technology IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany. | Health Technology |
Agendia NV
 Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Janssen Vaccines & Prevention BV
Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Health Technology |
| Chrysalis | Health Services |
Vivendy Therapeutics Ltd.
Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Health Services |
viDA Therapeutics, Inc.
viDA Therapeutics, Inc. BiotechnologyHealth Technology viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada. | Health Technology |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
Zambon Company SpA
 Zambon Company SpA Pharmaceuticals: MajorHealth Technology Zambon Co. SpA operates as an industrial holding company with interests in pharmaceuticals and chemicals. The company was founded by Gaetano Zambon on November 11, 1906 and is headquartered in Bresso, Italy. | Health Technology |
